Keyword: Imfinzi (durvalumab)
AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to its cancer drugs—and once again, China.
The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.
AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.
AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat.
Pascal Soriot’s reign at AstraZeneca is once again rumored to be coming to an end, and the company has reportedly begun looking for his successor.
AstraZeneca spent the last 16 months trying to keep investors’ hopes alive that its Mystic trial could succeed after an initial flop. But it didn’t.
AZ put skeptics to rest with a long-promised "return to growth." But it’s still far from its $40B sales goal—and its CEO doubled down on it anyway.
AstraZeneca already has an Imfinzi OK in lung cancer maintenance. But new survival data will strengthen its case—and its lead over its I-O rivals.
Kyowa is also testing the drug in early-phase trials for solid tumors, in combo with its own IDO inhibitor KHK2455, BMS’ Opdivo and AZ’s Imfinzi.